These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21923668)

  • 21. Current update on cellular and molecular mechanisms of hereditary angioedema.
    Walford HH; Zuraw BL
    Ann Allergy Asthma Immunol; 2014 May; 112(5):413-8. PubMed ID: 24484972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema.
    Kreuz W; Rusicke E; Martinez-Saguer I; Aygören-Pürsün E; Heller C; Klingebiel T
    Transfusion; 2012 Jan; 52(1):100-7. PubMed ID: 21756262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency.
    Bork K
    Expert Rev Clin Immunol; 2011 Nov; 7(6):723-33. PubMed ID: 22014012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema.
    Gösswein T; Kocot A; Emmert G; Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Bork K; Oldenburg J; Müller CR
    Cytogenet Genome Res; 2008; 121(3-4):181-8. PubMed ID: 18758157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
    Busse P; Kaplan A
    J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy.
    Kaplan AP
    J Allergy Clin Immunol; 2010 Nov; 126(5):918-25. PubMed ID: 20889195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.
    Larrauri B; Hester CG; Jiang H; Miletic VD; Malbran A; Bork K; Kaplan A; Frank M
    Mol Immunol; 2020 Mar; 119():27-34. PubMed ID: 31955064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema.
    Relan A; Bakhtiari K; van Amersfoort ES; Meijers JC; Hack CE
    BioDrugs; 2012 Feb; 26(1):43-52. PubMed ID: 22171564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment.
    Serrano C; Guilarte M; Tella R; Dalmau G; Bartra J; Gaig P; Cerdà M; Cardona V; Valero A
    Allergy; 2008 Jun; 63(6):735-41. PubMed ID: 18070231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary C1 inhibitor deficiency is associated with high spontaneous amidase activity.
    Charignon D; Ghannam A; Ponard D; Drouet C
    Mol Immunol; 2017 May; 85():120-122. PubMed ID: 28222330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema.
    Frazer-Abel A; Giclas PC
    Allergy Asthma Proc; 2011; 32 Suppl 1():17-21. PubMed ID: 22195757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.
    Farrell C; Hayes S; Relan A; van Amersfoort ES; Pijpstra R; Hack CE
    Br J Clin Pharmacol; 2013 Dec; 76(6):897-907. PubMed ID: 23594263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the acute treatment of hereditary angioedema.
    Riedl MA
    Allergy Asthma Proc; 2011; 32(1):11-6. PubMed ID: 21262093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study.
    Riedl MA; Levy RJ; Suez D; Lockey RF; Baker JW; Relan A; Zuraw BL
    Ann Allergy Asthma Immunol; 2013 Apr; 110(4):295-9. PubMed ID: 23535096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
    Stolz LE; Sheffer AL
    Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
    Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
    J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
    Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
    Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2).
    Krassilnikova S; Craig ET; Craig TJ
    Expert Rev Clin Immunol; 2010 May; 6(3):327-34. PubMed ID: 20441418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pathogenesis of hereditary angioedema.
    Davis AE
    Transfus Apher Sci; 2003 Dec; 29(3):195-203. PubMed ID: 14572810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SERPING1 mutations in 59 families with hereditary angioedema.
    López-Lera A; Garrido S; Roche O; López-Trascasa M
    Mol Immunol; 2011 Oct; 49(1-2):18-27. PubMed ID: 21864911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.